Lenalidomide as a Chemopreventive Agent for High-Risk Early Stage B-cell Chronic Lymphocytic Leukemia (CLL)
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2010 |
A Pilot Study of Lenalidomide as a Chemopreventive Agent for Patients With High-Risk, Early Stage B-Chronic Lymphocytic Leukemia (CLL)
Pilot study of lenalidomide as a chemopreventive agent in untreated, high-risk, early stage
B-CLL patients.
The purpose of this study is to determine if lenalidomide is safe and effective in the
treatment of patients with high-risk early stage B-Cell CLL who are asymptomatic.
Lenalidomide is a drug that alters the immune system and it may also interfere with the
development of tiny blood vessels that help support tumor growth. Therefore, in theory, it
may reduce or prevent the growth of cancer cells.
Lenalidomide can be an important chemopreventive agent for the treatment of early stage CLL
with defined markers for poor prognosis.
We found this trial at
1
site
Roswell Park Cancer Center Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer...
Click here to add this to my saved trials
